Loading...
•
Sep 30, 2024
Blueprint Medicines Q3 2024 Earnings Report
Blueprint Medicines' third quarter results were reported with AYVAKIT net product revenues reaching $128.2 million and full year revenue guidance raised.
Key Takeaways
Blueprint Medicines reported strong AYVAKIT revenue performance leading to raised full year revenue guidance to $475 million to $480 million. The company is on track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end. The company's cash position remains strong, enabling a self-sustainable financial profile.
AYVAKIT net product revenues reached $128.2 million in Q3 2024.
AYVAKIT net product revenue guidance raised to $475 million to $480 million for 2024.
Phase 1 study of BLU-808 advanced, with data expected in early 2025.
The company is on track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end.
Revenue by Geographic Location
Forward Guidance
Blueprint Medicines anticipates approximately $475 million to $480 million in global AYVAKIT net product revenues in 2024. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023.
Positive Outlook
- Continued growth in patients on therapy
- Continued favorability in compliance and other performance factors
- Stronger than expected performance outside of the U.S.
- Full-year operating expenses will decline in 2024 as compared to 2023
- Cash burn will decline in 2024 as compared to 2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...